The FDA again turned back Capricor’s Duchenne cell therapy deramiocel, citing “serious data integrity violations” that compromised study findings. The agency’s statement marks a second rejection since 2025, intensifying scrutiny around the quality of underlying datasets supporting the product’s clinical record. Capricor’s setback arrives at a time when manufacturing and clinical-data integrity have become central to late-stage regenerative medicine review. While the immediate regulatory pathway was not detailed in the provided report, the FDA’s action creates a clear overhang for trial planning, data remediation, and any potential resubmission strategy. For biotech investors and developers, the episode is a reminder that despite therapeutic promise, regulatory momentum can hinge on data traceability and documentation integrity—particularly in cell-therapy evidence packages.